pharmacological treatment optimization to management Target

Hypertension. A delay greater than 1.4 months in anti-hypertension treatment optimization is associated with an increased risk of stroke, heart failure or myocardial infarction.

Heart Failure. Sizeable proportions of patients eligible for Guidelines Recommended Medication Treatment (GDMT) of chronic heart failure with reduced ejection fraction (HFrEF) do not receive the recommended medication treatment, and those that receive therapy generally receive low doses.

Interoperable with Epic EHR [adaptable to other EHR solutions] 1
Clinically robust and secure cloud computing 1, 2
Ongoing surveillance and efficacy-driven trigger for pharmacological treatment optimization 1, 2
Physician reimbursement under chronic care management codes *

1. OPTIMA AI is interoperable with Epic® and remote monitoring devices. OPTIMA provides clinically robust and secure cloud computing. National Heart Lung and Blood Institute Funded Projects. Award # R44HL132622-02. Award # R43 HL147627-01.

2. OPTIMA AI offers ongoing surveillance and efficacy-driven pharmacological treatment optimization. National Heart Lung and Blood Institute Funded Projects. Award # R44 HL149428-01. Award # R43 HL147627-01.

* Reimbursement policies vary by provider. Check with the patient’s insurance carriers for detailed requirements and eligibility.

clinical use cases
HYPERTENSION MANAGEMENT

OPTIMA 4 BP supports decision making and treatment optimization action for physicians managing patients with sub-optimally controlled hypertension. OPTIMA 4 BP brings blood pressure to Target within 6 months.

REACHING Heart Failure GDMT

OPTIMA 4 HEART breaks down HFrEF treatment management to GDMT Target into successive medication and dose based treatment optimization steps. OPTIMA 4 HEART brings Heart Failure treatment to GDMT within 4 months.

key clinical validation studies
OPTIMA 4 BP DECISION-MAKING

OPTIMA 4 BP simulates the successive steps of the pharmacological intervention clinical reasoning process while engaging the provider and patient in shared HTN management.

National Heart Lung and Blood Institute, 2017.
Award # R44 HL132622-02.

read the abstract

OPTIMA 4 BP ACTION SUPPORT

In between office visits, OPTIMA 4 BP successfully optimizes pharmacological interventions leading to blood pressure Target within 6 months.

National Heart Lung and Blood Institute, 2019.
Award # R44 HL149428-01.

read the abstract

OPTIMA 4 HEART GDMT DECISION

OPTIMA 4 HEART provides sustained and safe treatment optimization to life-saving GDMT medications Target within 4 months.

National Heart Lung and Blood Institute, 2019.
Award # R43 HL147627-01.

read the abstract

OPTIMA 4 BP AFRICA

OPTIMA 4 BP AFRICA adapts the efficacy of optima4BP, developed by Optima for use in the US, to the needs of a low-resource setting.

National Heart Lung and Blood Institute, 2020.
Award # Pending.

read the abstract